Michael Wang, MD
Professor, Pediatrics-Heme/Onc and Bone Marrow Transplantation

Professional Titles

• Director

Recognition & Awards

• Community Leadership Award, Nation Bleeding Disorders Foundation Colorado Chapter (2023)
• Young Investigator Award, American Society of Pediatric Hematology/Oncology (2000)
  

Research Interests

Teaching

Publications

• Leebeek FWG, Peyvandi F, Tiede A, Castaman G, Escobar M, Wang M, Zulfikar B, Susen S, Miesbach W, Wang S, Wang Y, ZhangWynn T, Baptista J, Wang Y, Zhang J, and Ozen G. Prophylaxis with recombinant von Willebrand factor (rVWF) in patients with type 3 von Willebrand disease (VWD): results of a post-hoc analysis from a phase 3 trial. Eur J Haematol. 2023 Feb 23. doi: 10.1111/ejh.13949. Online ahead of print. PMID: 36823994
• Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Gut R, Miesbach W. First Phase 3 Gene Therapy Trial for Hemophilia B: Successful Treatment Despite Neutralizing Antibodies to Adeno-associated Virus. N Engl J Med. 2023 Feb 23;388(8):706-718. doi: 10.1056/NEJMoa2211644.
• Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou S-C, Ozelo C, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DQ, Symington E, Leavitt A, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele K-M, Reddy DB, Henshaw J, Robinson TM, Wong WY and Pipe SW. Two-year Safety and Efficacy of Valoctocogene Roxaparvovec Gene Therapy in Hemophilia A. N Engl J Med. 2023 Feb 23;388(8):694-705. doi: 10.1056/NEJMoa2211075. PMID: 36812433
• Santoro C, Fuh B, Le PQ, Maes P, Berrueco R, Mingot-Castellano EM, von Mackensen S, Tueckmantel C, Cabre Marquez JF and Wang M. Efficacy and safety in patients with haemophilia A switching to Kovaltry (BAY 81-8973): Final results of the global real-world study, TAURAS. Eur J Haematol. 2023 Jan;110(1):77-87. doi: 10.1111/ejh.13876. Epub 2022 Oct 17. PMID: 36192847
• Mahlangu JN, Lamas JL, Moralews JC, Malan DR, Zupancic-Salek S, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P and Arkin S. Treatment with marstacimab for people with severe hemophilia A or B: a plain language summary of the results from a short-term study and a longer-term study. Future Rare Dis. 10.2217/frd-2023-0004.
• Hermans C, Miesbach W, Journeycake J, Ducore J, Escobar M, Wang M, Quon D, Cisse OA, Chambron N, Mitchel. IS, Al-Sabbagh A, Bonzo D, and Mahlangu J. High dose of Eptacog Beta (Factor VIIa, Recombinant) is effective in the treatment of bleeding episodes regardless of severity in adult and adolescent with Hemophilia A or B with Inhibitors. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Germany. 2023.
• Lemons R, Wang M, Curtin J, Lepatan LM, Male C, Peyvandi F, Von Depka Prondzinski M, Wang R, McKeand W, Seifert W, and Oldenburg J. Safety and Efficacy of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Haemophilia B. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Germany. 2023.
• Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Klamroth R, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe SW. Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1. 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Germany. 2023.
• Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe SW. Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1. EAHAD. Manchester, U.K. 2023.
• Chowdary P, Khoo L, Wang M, Chambost H, Chan AKC, Moryusef A, Willemze A, and Oldenburg J. Prospective, Observational Study of the Clinical Characteristics of Adults and Adolescents with Severe Hemophilia A. XXVIV Congress of the International Society on Thrombosis and Haemostasis. Montreal, Canada. 2023.
• Buckner TW, Daoud N, Lee L, Morton P, O’Neill C, Wang M, and Recht M. Emicizumab prophylaxis in people with hemophilia A aged =50 years with comorbidities: experience from the ATHN 7 hemophilia natural history study. XXVIV Congress of the International Society on Thrombosis and Haemostasis. Montreal, Canada. 2023.
• Mann K, Wang M, Roybal J. When One Chronic Disease Obscures Another: Gait Changes in a Patient with Hemophilia B. American Academy for Cerebral Palsy and Developmental Medicine Annual Meeting. Chicago, IL. 2023.
• Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe SW. Endogenous FVIII activity and procedure-related FVIII use and bleeding: post hoc analysis of GENEr8-1. 56th Nordic Coagulation Meeting. 2023. Oslo, Norway.
• Goldenberg NA, Kittelson JM, Abshire TC, Bonaca M, Casella JF, Dale RA, Halperin JL, Hamblin F, Kessler CM, Manco-Johnson MJ, Sidonio RF, Spyropoulos AC, Steg PG, Turpie AGG, Schulman S; Kids_DOTT Trial Investigators and the Atlas Group. JAMA. 2022 Jan 11;327(2):129-137. doi: 10.1001/jama.2021.23182. PMID: 35015038
• Buckner TW, Kleiboer B, Layer M, Cafuir L, Cuker A, Escobar M, Eyster E, Kraut E, Leavitt A, Lentz S, Quon D, Ragni M, Thornhill D, Wang M and Key Nigel. Buckner TW. Prospective, multicenter observational study of postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery. J Thromb Haemost. 2022 Apr;20(4):857-865. doi: 10.1111/jth.15654. PMID: 35080347
• Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Haroon Mitha I, Negrier C, Nowak-Gottl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Villarreal Martinez L, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkeinson TA and Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in pediatric subjects (<12 years) with hemophilia A or B with inhibitors. Haemophilia. 2022 Apr 27. doi: 10.1111/hae.14563.
• Leebeek FWG, Peyvandi F, Escobar M, Tiede A, Castaman G, Wang M, Wynn T, Baptista J, Wang Y, Zhang J, Mellgard B, and Ozen G. Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood. 2022 Apr 19:blood.2021014810. doi: 10.1182/blood.2021014810. PMID: 35439298.
• Ozelo MC, Mahlangu J, Pasi KJ, Giermasz A, Leavitt A, Laffan, Symington E, Quon DQ, Wang J-D, Peerlinck K, Pipe SW, Madan B, Key NS, Pierce GF, O’Mahoney B, Kaczmarek R, Henshaw J, Lawal A, Jayaram K, Huang M, Yang X, Wong WY, Kim B, GENEr8-1 Trial Group. Valoctocogene Roxaparvovec Gene Therapy in Hemophilia A. N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708. PMID: 35294811
• Wang M, Negrier C, Driessler F, Goodman C and Skinner M. Hemophilia gene therapying the context of the patient journey. Patient Prefer Adherence. 2022 Jun 9;16:1439-1447. doi: 10.2147/PPA.S355627.eCollection 2022.
• Pipe SW, Hermans C, Chitlur M, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks SL, Mitha IH, Négrier C, Nowak-Göttl U, Recht M, Chrisentery-Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Young G, Alexander WA, Bonzo D, Macie C, Mitchell IS, Sauty E, Wilkinson TA and Shapiro AD. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects ( <12 years) with haemophilia A or B with inhibitors. Haemophilia. 2022 Jul;28(4):548-556. doi: 10.1111/hae.14563.Epub 2022 Apr 27.
• Mahlangu JN, Lamas JL, Moralews JC, Malan DR, Zupancic-Salek S, Wang M, Boggio LN, Hegemann I, Mital A, Cardinal M, Zhu T, Sun P and Arkin S. Marstacimab, a human tissue factor pathway inhibitor, for severe hemophilia. (in press, Br J Haematol.)
• Mahlangu J, Kaczmarek R, von Drygalski A, Shapiro S, Chou S-C, Ozelo C, Kenet G, Peyvandi F, Wang M, Madan B, Key NS, Laffan M, Dunn AL, Mason J, Quon DQ, Symington E, Leavitt A, Oldenburg J, Chambost H, Reding MT, Jayaram K, Yu H, Mahajan R, Chavele K-M, Reddy DB, Henshaw J, Robinson TM, Wong WY and Pipe SW. Two-year Safety and Efficacy of Valoctocogene Roxaparvovec Gene Therapy in Hemophilia A. (in press, NEJM)
• Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Gut R, Miesbach W. First Phase 3 Gene Therapy Trial for Hemophilia B: Successful Treatment Despite Neutralizing Antibodies to Adeno-associated Virus. (in press, NEJM)
• Wang M, Nuss R and McKinney C. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 24rd Edition. McGraw-Hill Education, Lange. 2022.
• Hermans C, Mahlangu J, Ahuja S, Carcao M, Castaman G, Davis J, Hart D, Khan O, Miesbach W, Nowak-Gottl U, Reding M, Schved F-F, Villarreal Martinez L, Wang M, Windyga J, Witkop M, Young G, Bonzo D, Mitchell I and Kessler C. Pain relief with eptacog beta in haemophilia patients with inhibitors. EAHAD. 2022. Virtual.
• Hermans C, Mahlangu J, Ahuja S, Carcao M, Castaman G, Davis J, Hart D, Khan O, Miesbach W, Nowak-Gottl U, Reding M, Schved F-F, Villarreal Martinez L, Wang M, Windyga J, Witkop M, Young G, Bonzo D, Mitchell I and Kessler C. Pain relief with eptacog beta in haemophilia patients with inhibitors. XXXV International Congress of the World Federation of Hemophilia. Montreal. 2022.
• Nowak-Gottl U, Young G, Pipe S, Hermans C, Carcao M, Castaman G, Davis J, Ducore J, Dunn A, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha IH, Negrier C, Recht M, Singleton T, Stasyshyn O, Vilchevska K, Villarreal Martinez L, Wang M, Wingyga J, Bonzo D, Macie C, Wilkinson T and Shapiro A. Analysis of bleeding episode resolution with eptacog beta by age group in young patients with hemophilia A or B with inhibitors. 66th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Leipzig, Germany. 2022.
• Pipe SW, Ozelo MC, Kenet G, Reding M, Mason J, Leavitt AD, Madan B, Laffan M, Quon DV, von Drygalski A, Chou S-C, Shapiro S, Dunn A, Nunez R, Wang M, Key NS, Kaczmarek R, Syminton E, Mahajan R, Chavale K-M, Reddy D, Wong WY, Robinson TM and Kim B. Relationship between endogenous, transgene FVIII expression and bleeding events following valoctocogene roxaparvovec gene transfer for severe hemophila A: a post-hoc analysis of the GENEr8-1 phase 3 trial. 66th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Leipzig, Germany. 2022.
• Miesbach W, Kessler C, Windyga J, Hart D, Villarreal Martinez L, Schved J-F, Mahlangu J, Acharya S, Ahuja S, Ducore J, Escobar M, Carcao M, Castaman G, Hermans C, Quon D, Sidonio R, Reding M, Singleton T, Wang M, Bonzo D, Macie C and Nowak-Gottl U. Comparing 225 µg/kg to 75 µg/kg dosing regimens across pivotal clinical trials. 66th Annual Meeting of the Society of Thrombosis and Haemostasis Research. Leipzig, Germany. 2022.
• Buckner TW, Carpenter SL, Kempton CL, Lee L, Malec L, McLean TW, Morton P, Stabler JM, Wang M and Recht M. Safety and Efficacy of Emicizumab in People with Hemophilia A Enrolled in the Hemophilia Natural History Study (ATHN 7). XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.
• Lemons R, Wang M, Curtin J, Huth-Kuehne A, Lepatan LM, Male C, Peyvandi F, vo Depka Prondzinski M, D McKeand, Seifert W and Oldenburg J. Safety and Efficacy of Recombinant Factor IX Fusion Protein (rIX-FP) in Previously Untreated Patients with Hemophilia B. XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.
• Wang M, Siffel C, Turecek P, Gazda H, Fung S, Swallow E, Greatsinger A, Billmyer E and Hertfelder H-J. Real-world treatment of severe congenital protein C deficiency with protein C concentrate including prophylaxis: A physician survey in Europe and the US. XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.
• Mahlangu J, Chambost H, Chou S-C, Dunn A, von Drygalski A, Kaczmarek R, Kenet G, Key NS, Laffan M, Leavitt AD, Madan, B, Mason J, Oldenburg J, Ozelo MC, Peyvandi F, Quon DV, Reding MT, Shapiro S, Symington E, Wang M, Yu H, Mahajan R, Chavele K-M, Reddy D, Robinson T, Pipe SW. Relationship between transgene-produced FVIII and bleeding rates 2 years after gene transfer with valoctocogene roxaparvovec: Results from GENEr8-1. XXVIII Congress of the International Society on Thrombosis and Haemostasis. London, UK. 2022.
• Young G, Sidonio R, Oldenburg J, Jiménez Yuste V, Mahlangu J, Kruse-Jarres R, Wang M, Shima M, Tzeng E, Ko RH, Bernardi R, Fox R, and Mancuso ME. Bleed prevention and safety in children on every 2 week and every 4 week emicizumab prophylaxis: 52-week outcomes in HAVEN 2. Annual Meeting of the National Hemophilia Foundation. 2022.
• Kessler C, Abajas Y, Acharya.S, Ahuja S, Chitler M, Giermasz A, Khan O, Mauer K, Danielle N, Rafique A, Reding MT, Chrisentary-Singleton T, Tran DQ, Witkop M, Young G, Bonzo D, Mavie C, Wilkerson TA, and Wang M. Pain relief with eptacog beta in hemophilia patients with inhibitors. Annual Meeting of the National Hemophilia Foundation. 2022.
• Leebeek FWG, Escobar M, Tiede A, Wang M, Zulfikar B, Wang S, Wang Y, and Ozen G. Prophylaxis with Recombinant von Willebrand factor in Patients with Type 3 von Willebrand disease: Post Hoc Analysis from a Phase 3 Trial. Thrombosis & Hemostasis Summit of North America. Chicago, IL. 2022.
• Pipe SW, Callaghan M, Ducore J, Escobar M, Hermans C, Journeycake J, Meeks S, Recht M, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell I, and Shapiro A. Evaluation of the hemostatic efficacy of eptacog beta (recombinant factor VIIa) for the treatment of bleeding in pediatric subjects (<12 years) with hemophilia A or B with inhibitors in PERSEPT 2. Thrombosis & Hemostasis Summit of North America. Chicago, IL. 2022.
• Escobar M, Callaghan M, Ducore J, Hermans C, Journeycake J, Lessinger C, Luck J, Quon D, Recht M, Schved J-F, Sidonio R, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Wilkenson T, and Kessler C. The Safety of Activated Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Surgical Settings. Thrombosis & Hemostasis Summit of North America. Chicago, IL. 2022.
• Carpenter SL, Chandler M, Guerrera M, Malec L, Manuel M, Recht M, Reiss UM, Sidonio R, Tarango C, van den Berg M, Wang M, Thornburg C on behalf of the ATHN 8 investigators. U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor development and treatment characteristics. 64th American Society of Hematology Annual Meeting. New Orleans, LA. 2022.
• Reding M, Mancuso ME, Acharya S, Ahuja S, Alvarez-Roman MT, Boggio L, Chitlur M, Majluf Cruz A, Dunn A, Escobar M, Harroche A, Janbain M, Kessler C, Maes P, McGuinn C, Nance D, Nowk-Gottl, Sidonio R, Tran D, Wang M, Wingyda J, Wang H, Wilkenson T, and Pipe S. Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1. 64th American Society of Hematology Annual Meeting. New Orleans, LA. 2022.
• Quon DV, Wang JD, Wang M, Pepperell D, Park YS, Kenet G, Mahlangu J, Khoo T-L, Robinson TM, Chavele K-M, and Pipe S. Relationship Between Endogenous FVIII Activity and Bleeding Episodes Resulting from Procedures: A Post Hoc Analysis of the GENEr8-1 Phase 3 Trial. 64th American Society of Hematology Annual Meeting. New Orleans, LA. 2022.
• DeSancho MT, Munn J, Billet HH, ZCheng D, Holmes C, Jaffray J, Malone M, Patel K, Sharathkumar A, Thornburg CD, Wang M, Watson C, Rajpurkar M. "Transition of Care for Pediatric and Adult Patients with Venous Thromboembolism: A National Quality Improvement Project from the American Thrombosis and Hemostasis Network (ATHN). Thromb Res. 2021 Apr;200:23-29. doi: 10.1016/j.thromres.2021.01.001. Epub 2021 Jan 18. PMID: 33517168
• Ng C, Spomer N, Shearer R, LeBlanc A, Funk S, Manco-Johnson M, Branchford B, Warren B, Buckner T, Moyer G, Wang M, Gibson E and Mashburn C. Quality Improvement Initiative to Improve Communication and Coordination of Care in a Hemophilia Treatment Center. Acta Haematol. 2021 Apr 29:1-6. doi: 10.1159/000515350. Online ahead of print. PMID: 33915533
• Warren BB, Chan A, Manco-Johnson M, Branchford BR, Buckner TW, Moyer G, Gibson E, Thornhill D, Wang M and Ng CJ. Emicizumab Initiation and Bleeding Outcomes in Hemophilia A Patients with and without Inhibitors, a Single-Center Report. Res Pract Thromb Haemost. 2021 Aug 3;5(5):e12571. doi: 10.1002/rth2.12571.eCollection 2021 Jul.
• Maher KN, Gibson E, Warren BB, Funk SM, Shearer R, Buckner TW, Wang M, Manco-Johnson MJ and Ng CJ. Prophylaxis for children with moderate hemophilia: Use of a guideline to increase early initiation. Pediatr Blood Cancer. 2021 Jan;68(1):e28577. doi: 10.1002/pbc.28577. Epub 2021 Sep 2.
• Holsteen PE, Meier M, Brennan L, VanHorn T, Voinescu C, Kuldanek S, Wang M and Martiniano SL. Safety and effectiveness of a risk-stratified venous thromboembolism prophylaxis algorithm in patients with cystic fibrosis. Thromb Res. 2021 Oct;206:36-41. doi: 10.1016/j.thromres.2021.07.007. Epub 2021 Jul 10. PMID: 34399123
• Witkop M, Wang M, Hernandez G, Recht M, Baumann K and Cooper DL. Impact of hemophilia on patients with mild-to-moderate disease: results from the P-FiQ and B-HERO-S studies. Haemophilia. 2021 Jan;27 Suppl 1:8-16. doi: 10.1111/hae.14251. PMID: 33522654
• Escobar M, Callaghan M, Ducore J, Hermans C, Journeycake J, Lessinger C, Luck J, Mahlangu J, Quon D, Recht M, Schved J-F, Shapiro A, Sidonio R, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Wilkinson TA and Kessler C. The Safety of Activated Eptacog Beta in the Management of Bleeding Episodes and Perioperative Hemostasis in Adult and Pediatric Hemophilia Patients with Inhibitors. Haemophilia. 2021;27:921-931.
• Escobar M, Luck J, Averianov Y, Lopez Fernandez MF, Giermasz A, Hart D, Journeycake J, Craig Kessler, Leissinger C, Mahlangu J, Villarreal Martinez L, Miesbach W, Haroon Mitha I, Quon D, Reding M, Schved J-F, Stasyshyn O, Vilchevska KV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Bonzo D, Mitchell I, Wilkinson TA and Hermans C. PERSEPT 3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia A or B with Inhibitors. Haemophilia. 2021;27:911-920.
• Carcao M, Shapiro A, Hwang N, Pipe S, Ahuja S, Lieuw K, Stabler J, Belletrutti M, Sun HL, Ding H, Wang M, Price V, Steele M, Tsao E, Feng J, Al-Khateeb Z, Dumont J and Jain N. Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Patients with Severe Haemophilia A with Inhibitors at High Risk for ITI Failure: A Follow-up Retrospective Analysis. Haemophilia. 2021 Jan;27(1):19-25. doi: 10.1111/hae.14192. Epub 2020 Nov 18.
• Hermans C, Miesbach W, Journeycake J, Ducore J, Escobar M, Wang M, Quon D, Cisse OA, Chambron N, Mitchell IS, Al-Sabbagh A, Bonzo D and Mahlangu J. High dose eptacog beta (factor VIIa, recombinant) is effective in the treatment of bleeding episodes regardless of severity in adult and adolescents with hemophilia A or B with inhibitors. EAHAD. 2021. Manchester, UK.
• Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Bajwa N, Gut R, Miesbach W. Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Severe or Moderate-Severe Hemophilia B: First data from the phase 3 HOPE-B gene therapy trial. EAHAD. 2021. Manchester, UK.
• Escobar M, Callaghan M, Ducore J, Hermans C, Journeycake J, Lessinger C, Luck J, Quon D, Recht M, Schved JF, Sidonio R, Wang M, Young G, Alexander WA, Al-Sabbagh A, Bonzo D, Wilkenson T and Kessler C. The Safety of Activated Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Surgical Settings. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.
• Pipe S, Callaghan M, Ducore J, Escobar M, Hermnans C, Journeycake J, Meeks S, Recht M, Wang M, Young G, WA Alexander, Al-Sabbagh A, Bonzo D, Mitchell and Shapiro A. Evaluation of the hemostatic efficacy of eptacog beta (recombinant factor VIIa) for the treatment of bleeding in pediatric subjects (<12 years) with hemophilia A or B with inhibitors in PERSEPT 2. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.
• Roberts JC, Escobar E, Acharya S, Hwang NX, Wang M, Hale S, Asghar S and Kouides PA. Gastrointestinal bleeding in patients with von Willebrand disease: treatments and outcomes. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.
• Escobar M, Quon D, Wang M, Wufus A, Ostrow V and Warren B. Surgical procedures in patients with hemophilia: Multistakeholder perspectives from 2018 roundtables. Hemostasis and Thrombosis Research Society Research Symposium. 2021. Virtual.
• Leebek FW, Miesbach W, Recht M, Key NS, Lattimore S, Castaman G, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi J, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemoins R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Cooper D, Ferriera V and Pipe SW. Clinical outcomes in adults with hemophilia B with and without pre-existing neutralizing antibodies to AAV5: 6-month data from the phase 3 etranacogene dezaparvovec HOPE-B gene therapy trial. European Hematology Association Congress. 2021. Virtual.
• Castaman G, Pipe SW, Callaghan M, Ducore J, Escobar M, Hermans C, Mahlangu J, Nowak-Gottl U, Journeycake J, Khan O, Meeks S, Recht M, Wang M, Young G, Chambron N, Al-Sabbagh A, Bonzo D, Mitchell IS and Shapiro A. Activated Eptacog-beta, w rFVIIa, is effective and safe in the treatment of bleeding episodes of all severities in pediatric hemophilia A or B patients with inhibitors. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.
• Mahlangu J, Escobar M, Callaghan M, Ducore J, De Moerloose, Hermans PC, Castaman G, Schved -F, Journeycake J, Leissinger C, Luck J, Quon D, Recht, Sidonio, Srivastava A, Wang M, Young G, Al-Sabbagh A, Bonzo D, Chambron N, Wilkinson T and Kessler C. The Safety of Activated Eptacog Beta in Hemophilia Patients with Inhibitors in Adult, Pediatric, and Perisurgical Settings. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.
• Miesbach W, Hermans C, Pipe SW, Journeycake J, Ducore J, Escobar M, Wang M, Quon D, Boggio L, Chambron N, Mitchell IS, Al-Sabbagh A, Bonzo D and Mahlangu J. Activated Eptacog Beta (Factor VIIa, Recombinant) Provides Rapid Bleed Resolution and Pain Relief in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.
• Buckner TW, Kleiboer B, Layer M, Cafuir L, Cuker A, Escobar M, Eyster E, Kraut E, Leavitt A, Lentz S, Quon D, Ragni M, Thornhill D, Wang M and Key Nigel. Prospective, multicenter observational study of postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual
• Warren BB, Thornhill D, Jacobson L, Baird C, Hill D, Ng C, Buckner T, Wang M and Manco-Johnson M. Emicizumab: What can patients expect regarding hemostasis, bleeding and sports capacity? XXVII Congress of the International Society on Thrombosis and Haemostasis. 2021. Virtual.
• Pipe SW, Ozelo MC, Kenet G, Reding M, Mason J, Leavitt AD, Madan B, Laffan M, Quon DV, von Drygalski A, Chou S-C, Shapiro S, Dunn A, Nunez R, Wang M, Key NS, Kaczmarek R, Syminton E, Mahajan R, Chavale K-M, Reddy D, Wong WY, Robinson TM and Kim B. Relationship between endogenous, transgene FVIII expression and bleeding events following valoctocogene roxaparvovec gene transfer for severe hemophila A: a post-hoc analysis of the GENEr8-1 phase 3 trial. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.
• Young G,Pipe SW, Hermans C, Carcao M, Castaman G, Davis JA, Ducore J, Dunn AL, Escobar M, Journeycake J, Khan O, Mahlangu J, Meeks S, Mitha IH, Negrier C, Nowak-Gottl U, Recht M, Singleton T, Stasyshyn O, Vilchevska KV, Martinez LV, Wang M, Windyga J, Alexander WA, Al-Sabbagh A, Wang H, Macie C, Mitchell IS, Wilkerson TA and Shapiro AD. Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.
• Journeycake J, Raffini L, Sidonio R, Chrisentery-Singleton T, Wang M, von Drygalski A, Cheng D, Recht M, Fedor, Hirsh N and Neufeld E. Reduced Dosing Frequency Following a Switch to Rix-FP for the Treatment of Hemophilia B: Results from the Athn 2 Study. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.
• Wheat E, Dunham BM, Tedeschi W, Richfield K, Spomet N, Gibson E, Blue A, Regier M, Wang M, Buckner TW. Feasibility of Delivering Transition Education During Annual Comprehensive Clinic Appointments and Patient-Reported Outcomes: A Quality Improvement Study. American Society of Hematology Annual Meeting. Atlanta, GA. 2021.
• Wang M, McKinney C, Ambruso DR and Nuss R. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 23rd Edition. McGraw-Hill Education, Lange.
• Manco-Johnson MJ, Warren BB, Buckner TB, Funk S and Wang M. Outcome measures: Beyond ABR. Haemophilia. 2020. (in press)
• Croteau SE, Wang M and Wheeler AP. 2020 Clinical Trials Update: Innovations in Hemophilia Therapy. Am J Hematol. 2020;1-17.
• Maher KN, Gibson E, Warren BB, Funk S, Shearer R, Buckner T, Wang M, Manco-Johnson M and Ng CJ. Prophylaxis for Children with Moderate Hemophilia: Use of a Guideline to Increase Early Initiation. Pediatr Blood Cancer. 2020;e28577.
• Walsh C, Coppens M, Escobar M and Wang M. Optimal trough levels in hemophilia B: Raising expectations. Haemophilia. 2020.
• Carcao M, Shapiro A, Hwang N, Pipe S, Ahuja S, Lieuw K, Stabler J, Belletrutti M, Sun HL, Ding H, Wang M, Price V, Steele M, Tsao E, Feng J, Al-Khateeb Z, Dumont J and Jain N. Real-World Data of Immune Tolerance Induction Using rFVIIIFc in Patients with Severe Haemophilia A with Inhibitors at High Risk for ITI Failure: A Follow-up Retrospective Analysis. Haemophilia. Haemophilia. 2020.
• Wang M, Peltier S, Baumann K, Sidonio RF, Witkop M, Cooper DL, Waters EK and Kahan S. Awareness, Care, and Treatment in Obesity Management to Inform Hemophilia Obesity Patient Empowerment (ACTION-TO-HOPE): Results of a Survey of US Hemophilia Treatment Center Professionals. Haemophilia. 2020;26 Suppl 1:20-30.
• Santoro C, Fuh B, Phu QL, Maes P, Berrueco RM, Mingot-Castellano, von Mackensen, Solms A and Wang M. BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A from real-world observation: interim results from the TAURUS study. Eur J Haemotol. 2020;105(2):164-172.
• Wang M, Recht M, Iyer NN, Cooper DL and Soucie JM. The Relationship of Joint Range of Motion to Factor Activity in Patients with Hemophilia A and B without Prophylaxis: A Longitudinal Assessment of the CDC-UDC Hemophilia Dataset. Res Pract Thromb Haemost. 2020;4(6):1035-1045.
• Lasky J, Teitel J, Wang M, Dalton D, Schmidt DS and Brainsky A. Efficacy and safety of fibrinogen concentrate for treatment of bleeding, surgery or routine prophylaxis in subjects with congenital fibrinogen deficiency. Res Pract Thromb Haemost. 2020;00:1-11.
• Shapiro A, Chaudhury, Wang M, Escobar M, Tsao E, Barnowski C, Feng J, Jain N and Quon DV. Real-world data demonstrates improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5 years. Haemophilia. 2020;26(6):975-983.
• Le PQ, Maes P, Castellano EM, Berrueco R, Wang M, Fuh B, Soto A and Santoro C. BAY 81-8973 prophylaxis in patients with haemophilia A: interim findings for children <12 years from the TAURUS real-world study. EAHAD. The Hague, Netherlands. 2020.
• Chan A, Warren BB, Ng C, Buckner TW, Moyer G, Furton L, Branchford B, Manco-Johnson M and Wang M. Influence of emicizumab on patient lifestyle at the University of Colorado. XXXIV International
• Santoro C, Wang M, Fuh B, Maes P, Mingot-Castellano M-E, Berrueco R, Detering E & Le PQ. BAY 81-8973 prophylaxis in patients with hemophilia A: interim usage and safety results from the TAURUS real-world study. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Roberts JC, Escobar M, Acharya S, Hwang NX, Wang M, Hale S, Oladapo A, S Asghar and Kouides PA. Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease: study design and initial demographic results. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Hermans C, Journeycake J, Ducore J, Escobar M, Young G, Wang M, Quon D, Alexander WA, Mitchell I, Al-Sabbagh and Bonzo D. The single dose efficacy of eptacog beta (recombinant human factor VIIa variant) when modeled over time challenges the practice of repeated low doses when treating bleeds in hemophilia patients with inhibitors. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Buckner T, Daoud N, Croteau SE, Kempton CL, Malec L, Stabler J, Wang M, Watson C and Recht M. ATHN 7: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Hemophilia-Demographics and Preliminary Results. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Boulden Warren B, Thornhill D, Smith J, Shearer R, Jacobson L, Moyer G, Fox L, O’Connor M, Horton R, Funk S, Chan A, Ng C, Buckner TW, Branchford B, Manco-Johnson MJ and Wang M. Emicizumab, beyond Annualized Bleeding Rates: Real World Joint Health and Physical Activity Data. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Moyer G, Boulden Warren B, Jacobson L, Baird C, Thornhill D, Smith J, Ng C, Buckner TW, Branchford B, Wang M and Manco-Johnson MJ. Emicizumab, beyond ABR: can we predict Emi effects from laboratory assays? XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Branchford B, Ng C, Boulden Warren B, Taylor J, Ambruso D, Briones N, Tran A, Jacobson L, Thornhill D, Moyer G, Norton K, Buckner TB, Wang M and Manco-Johnson MJ. Emicizumab, beyond ABR: what does Emi do to bones? XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Buckner TW, Rapacchietta O, Hill D, Thornhill D, Smith J, Shearer R, Ng C, Branchford B, Moyer G, Manco-Johnson M, Wang M. Improved Prophylaxis Adherence After Switching to Emicizumab: Real-World Data from a Single Center. XXVII Congress of the International Society on Thrombosis and Haemostasis. 2020.
• Buckner T, Carpenter SL, Croteau SE, Cuker A, Daoud N, Kempton CL, Malec L, McLean TW, Raffini L, Stabler J, Wang M, Watson C, Zia A and Recht M. Hemophilia Natural History Study (ATHN 7): Baseline Characteristics, Adverse Events, and Self-Reported Health Status of Individuals with Hemophilia A and B. 62nd American Society of Hematology Annual Meeting. 2020.
• Journeycake J, Hermans C, Ducore J, Escobar M, Young G, Wang M, Quon D, Alexander WA, Mitchell I, Al-Sabbagh and Bonzo D. Single 225µg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia ? or ? with Inhibitors: A PERSEPT1 Subset Analysis. 62nd American Society of Hematology Annual Meeting. 2020.
• Roberts JC, Escobar M, Acharya S, Hwang NX, Wang M, Hale S, Oladapo A, S Asghar, Mehdi S and Kouides PA. Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease. 62nd American Society of Hematology Annual Meeting. 2020.
• Escobar M, Quon D, Wang M, Warren B, Wufus A and Ostrow V. Surgical Procedures in Patient with Hemophilia: Multi-Stakeholder Perspectives from 2018 Round Tables. 62nd American Society of Hematology Annual Meeting. 2020.
• Pipe SW, Recht M, Key NS, Leebeek FWG, Castaman G, Lattimore S, van der Valk P, Peerlinck K, Coppens M, O’Connell NM, Pasi KJ, Kampmann P, Meijer K, von Drygalski A, Young G, Hermans C, Astermark J, Klamroth R, Lemons R, Visweshwar N, Crary S, Kazmi SRS, Symington E, Escobar MA, Gomez E, Kruse-Jarres R, Kotowski A, Quon D, Wang M, Wheeler AP, Sawyer EK, Verweij S, Colletta V, Bajwa N, Gut R, Miesbach W. First data from the Phase 3 HOPE-B gene therapy trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B. 62nd American Society of Hematology Annual Meeting. 2020.
• McKinney C, Nakano T, Forrester C, Nuss N and Wang M. Hematologic Disorders. In: Hay WW, Levin MJ, Deterding RR and Abzug MJ (eds.): CURRENT Diagnosis and Treatment Pediatrics: 25rd Edition. McGraw-Hill Education, Lange.

Professional Memberships

• American Society of Pediatric Hematology/Oncology, Member
• Children’s Oncology Group, Associate
• American Society of Hematology, Member
• National Hemophilia Foundation, Member
• Colorado Clinical and Translational Science Institute, Member
• Society For Pediatric Research (SPR), Elected Member
• International Society for Thrombosis and Homeostasis, Member
• Hemostasis Thrombosis Research Society, Member
• World Federation of Haemophilia, Member